Af­ter CRL, CorMedix says new fil­ing has been ac­cept­ed by FDA; Spine Bio­Phar­ma nets a mod­est Se­ries B

Af­ter a man­u­fac­tur­ing slip-up led to a CRL last year, a small biotech says its new ap­proach is ready for the FDA.

NJ-based CorMedix re­filed its ap­pli­ca­tion for its an­tibac­te­r­i­al and an­ti­fun­gal treat­ment to pre­vent blood­stream in­fec­tions in pa­tients un­der­go­ing chron­ic he­modial­y­sis, the com­pa­ny an­nounced Mon­day. The FDA has ac­cept­ed the fil­ing, con­sid­ers it a “Class 2 re­sponse” and will look at it as part of a six-month re­view, CorMedix added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER